LPTX
Leap Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.77
−3.15%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 209.0K | — | — | — | — |
| Cost of Revenue | 20.3M | — | — | 427.0K | — |
| Gross Profit | (20.1M) | — | — | (427.0K) | — |
| Operating Expenses | |||||
| R&D Expense | 44.8M | 25.7M | 57.2M | 73.2M | 45.0M |
| SG&A Expense | 10.9M | 10.9M | 12.8M | 13.4M | 11.8M |
| General & Admin Expense | 10.9M | 10.9M | 12.8M | 13.8M | 11.8M |
| Selling & Marketing Expense | — | — | — | (427.0K) | — |
| Other Expenses | (19.1M) | — | — | — | — |
| Total Operating Expenses | 36.5M | 36.5M | 70.1M | 86.6M | 56.8M |
| Cost and Expenses | 36.5M | 36.5M | 70.1M | 87.0M | 56.8M |
| Operating Income (EBIT) | (41.1M) | (36.5M) | (70.1M) | (87.0M) | (56.8M) |
| Non-Operating | |||||
| Interest Income | 916.0K | 916.0K | 3.1M | 4.0M | 925.0K |
| Interest Expense | 24.0K | 24.0K | — | — | 54.0K |
| Net Interest Income | 892.0K | 892.0K | 3.1M | 4.0M | 871.0K |
| Other Non-Op Income/Expense | 46.6M | 46.6M | 3.1M | 5.6M | 2.3M |
| Non-Operating Income (excl Interest) | (808.0K) | — | — | (5.6M) | (2.4M) |
| EBT (Pre-Tax Income) | 10.1M | 10.1M | (67.0M) | (81.4M) | (54.4M) |
| Income Tax Expense | 5.3M | 5.3M | 585.0K | — | 147.0K |
| Bottom Line | |||||
| Net Income | 4.8M | 4.8M | (67.6M) | (81.4M) | (54.6M) |
| Earnings from Cont. Ops | (17.8M) | 4.8M | (67.6M) | (81.4M) | (54.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 4.8M | 4.8M | (67.8M) | (81.4M) | (54.6M) |
| Per Share | |||||
| Basic EPS | $0.08 | $0.07 | ($1.81) | ($3.98) | ($4.82) |
| Diluted EPS | $0.07 | $0.07 | ($1.81) | ($3.98) | ($4.82) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 66.1M | 66.1M | 37.6M | 20.4M | 11.3M |
| Diluted Shares Outstanding | 70.7M | 70.7M | 37.6M | 20.4M | 11.3M |
| Profitability Metrics | |||||
| EBITDA | (40.3M) | (36.5M) | (70.1M) | (81.0M) | (54.4M) |
| D&A | — | — | 5.0K | 427.0K | 16.0K |
| EBIT | (40.3M) | (36.5M) | (70.1M) | (81.4M) | (54.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025